Blueberry Compound Delphinidin Reverses Microglial Aging to Fight Alzheimer's Pathology
Delphinidin, a natural anthocyanin, prevented microglial senescence via AMPK/SIRT1 signaling, reducing amyloid plaques and restoring cognition in AD mice.
Summary
Researchers at Fudan University found that delphinidin — a plant-derived anthocyanin abundant in berries and grapes — significantly reduced Alzheimer's-like pathology in APP/PS1 transgenic mice. By activating the AMPK/SIRT1 signaling pathway, delphinidin prevented microglia (the brain's immune cells) from entering a senescent, dysfunctional state. Treated mice showed improved spatial memory, reduced amyloid plaque burden, and less synapse loss. These effects were also observed in naturally aged mice. In cell culture, delphinidin blocked Aβ42-induced senescence in BV2 microglia. Blocking AMPK with Compound C reversed delphinidin's protective effects, confirming the pathway's necessity. The compound also directly interacted with SIRT1 protein. This is the first study to link delphinidin's neuroprotective effects specifically to the suppression of microglial senescence in AD.
Detailed Summary
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, defined by amyloid-beta (Aβ) plaques, tau tangles, and progressive cognitive decline. An increasingly recognized contributor to AD pathology is cellular senescence — particularly in microglia, the brain's resident immune cells. Senescent microglia lose their ability to clear Aβ and instead release harmful inflammatory cytokines (SASP factors), accelerating neurodegeneration. This study investigated whether delphinidin, a naturally occurring anthocyanin found in berries, grapes, and colorful vegetables, could combat AD by preventing microglial senescence.
The research team used APP/PS1 double transgenic mice (a standard AD model), naturally aged 18-month-old mice, and Aβ42-exposed BV2 microglial cell cultures. APP/PS1 mice received 15 mg/kg/day oral delphinidin or vehicle for 8 weeks starting at 7 months of age. Cognitive function was assessed via Morris Water Maze and Novel Object Recognition tests. Brain tissue was analyzed for amyloid plaque burden (Thioflavin-S staining, IHC), synaptic integrity, senescence markers (SA-β-galactosidase activity, p21/p16 cyclin levels, SASP cytokines, ROS/MDA/SOD), and microglial gene signatures. Mechanistic studies examined AMPK/SIRT1 pathway activation and used Compound C (AMPK inhibitor) to confirm pathway dependence. Molecular docking and binding assays assessed direct delphinidin-SIRT1 interaction.
Delphinidin-treated APP/PS1 mice demonstrated significantly improved spatial learning (shorter escape latencies in MWM), more platform crossings, and greater time in the target quadrant versus untreated AD mice. Object recognition discrimination indices were also restored. Histological analysis confirmed markedly reduced Aβ plaque density and improved synaptic marker expression. Crucially, delphinidin downregulated a senescent microglial gene signature, reduced SA-β-galactosidase activity, decreased SASP factor secretion, lowered oxidative stress indices (ROS, MDA), elevated antioxidant capacity (SOD), and reduced p21 and p16 cyclin levels — all hallmarks of cellular senescence reversal. These anti-senescence effects were reproduced in naturally aged mice and in Aβ42-stimulated BV2 cells in vitro.
Mechanistically, delphinidin robustly activated the AMPK/SIRT1 signaling axis. Delphinidin was shown to directly bind SIRT1 protein. Pharmacological inhibition of AMPK with Compound C abolished delphinidin's protective effects against microglial senescence, confirming that AMPK activation upstream of SIRT1 is essential for its mechanism of action. SIRT1 in turn modulates p53/p21-mediated cell cycle arrest and suppresses neuroinflammation.
These findings represent the first demonstration that delphinidin mitigates AD pathology specifically through prevention of microglial senescence. The compound's ability to act on multiple AD-relevant targets — amyloid clearance, inflammation, oxidative stress, and cellular aging — via a well-characterized longevity pathway positions it as a compelling candidate for further translational development. Importantly, delphinidin caused no significant changes in body weight or liver function in treated mice, suggesting a favorable safety profile at the tested dose.
Key Findings
- Delphinidin (15 mg/kg/day, 8 weeks) improved spatial memory and object recognition in APP/PS1 AD mice.
- Treatment reduced Aβ plaque burden, synapse loss, and senescent microglial gene signatures in AD mouse brains.
- Delphinidin suppressed SA-β-gal activity, SASP factors, ROS, and p21/p16 senescence markers in microglia in vivo and in vitro.
- AMPK/SIRT1 pathway activation was required; AMPK inhibitor Compound C reversed delphinidin's anti-senescence effects.
- Delphinidin directly interacted with SIRT1 protein, suggesting it acts as a molecular activator of this longevity pathway.
Methodology
Study used APP/PS1 transgenic AD mice and 18-month naturally aged mice (n=4–8/group) treated with oral delphinidin for 8 weeks, plus Aβ42-induced BV2 microglial senescence in vitro. Outcomes included behavioral testing (MWM, NOR), histology, senescence biomarkers, oxidative stress assays, and AMPK inhibitor rescue experiments.
Study Limitations
All experiments were conducted in male mice only, limiting generalizability across sexes. The study used a mouse microglial cell line (BV2) rather than primary human microglia, and no pharmacokinetic data on brain bioavailability of delphinidin were provided. Translation to human AD therapy requires clinical validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.